Skip to main content

Heron Therapeutics, Inc. (HRTX)

NASDAQ: HRTX · Delayed Price · USD
12.02
-0.08 (-0.66%)
After-hours:Sep 17, 2021 5:51 PM EDT
12.10
0.33 (2.80%)
At close: Sep 17, 4:00 PM
Market Cap1.23B
Revenue (ttm)83.03M
Net Income (ttm)-234.14M
Shares Out98.46M
EPS (ttm)-2.52
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,606,389
Open11.73
Previous Close11.77
Day's Range11.53 - 12.13
52-Week Range10.10 - 22.40
Beta1.39
AnalystsStrong Buy
Price Target33.00 (+172.7%)
Est. Earnings DateNov 4, 2021

About HRTX

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycli...

IndustryBiotechnology
IPO DateAug 26, 1987
CEOBarry Quart
Employees223
Stock ExchangeNASDAQ
Ticker SymbolHRTX
Full Company Profile

Financial Performance

In 2020, HRTX's revenue was $88.64 million, a decrease of -39.28% compared to the previous year's $145.97 million. Losses were -$227.28 million, 11.0% more than in 2019.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for HRTX stock is "Strong Buy." The 12-month stock price forecast is 33.00, which is an increase of 172.73% from the latest price.

Price Target
$33.00
(172.73% upside)
Analyst Consensus: Strong Buy

News

Heron Therapeutics (HRTX) Reports Q2 Loss, Misses Revenue Estimates

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -5.08% and -21.08%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2021 and Highlights Recent...

SAN DIEGO, Aug. 9, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatment...

1 month ago - PRNewsWire

Will Heron Therapeutics (HRTX) Report Negative Q2 Earnings? What You Should Know

Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Heron Therapeutics Announces Publication of Results from HOPE (Helping Opioid Prescription Elimination), Showing ZYNR...

SAN DIEGO, July 28, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatmen...

1 month ago - PRNewsWire

Heron Therapeutics' Zynrelef Shows Reduction In Post-Op Pain, Opioid Use Compared To Bupivacaine In Old-Aged Patients

Heron Therapeutics Inc (NASDAQ: HRTX) has announced the online publication of a new analysis from the Phase 3 EPOCH 1 and EPOCH 2 studies evaluating Zynrelef (bupivacaine and meloxicam) in adults aged 6...

1 month ago - Benzinga

Heron Therapeutics Announces Publication Showing Reduction of Pain and Opioid Use Compared to Bupivacaine in Patients...

SAN DIEGO, July 21, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatmen...

1 month ago - PRNewsWire

Heron Therapeutics Announces 340B Prime Vendor Contract with Apexus for ZYNRELEF™

SAN DIEGO, July 6, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatment...

2 months ago - PRNewsWire

Heron Therapeutics Announces U.S. Commercial Launch and Availability of ZYNRELEF™ for the Management of Postoperative...

SAN DIEGO, July 1, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatment...

2 months ago - PRNewsWire

Under Biden's Budget, These 2 Little-Known Biotechs Could Help End the Opioid Crisis

The White House's plans to address the U.S. opioid crisis could be good news for Heron Therapeutics and Collegium Pharmaceutical, makers of safer pain management drugs.

Other symbols:COLL
3 months ago - The Motley Fool

Heron Therapeutics to Present at the 2021 Jefferies Virtual Investor Conference

SAN DIEGO, May 25, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatment...

3 months ago - PRNewsWire

Trading Penny Stocks? 3 Biotech Stocks To Watch Before June 2021

Current & former penny stocks trading higher after surge of interest in biotech industry. The post Trading Penny Stocks?

Other symbols:GTBPPIRS
3 months ago - PennyStocks

Heron Therapeutics Announces $150 Million Convertible Debt Financing

SAN DIEGO, May 25, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron") today announced that it has sold $150 million of senior unsecured convertible promissory notes (the "Notes") in ...

3 months ago - PRNewsWire

Heron's Non-Opioid, Post-Operative Pain Drug Approved By FDA: Why This Is Important

Shares of Heron Therapeutics Inc (NASDAQ: HRTX) are higher after a long wait to get regulatory approval for its non-opioid pain drug. What Happened: San Diego, California-based Heron, a commercial-stage...

4 months ago - Benzinga

Heron Therapeutics Announces U.S. FDA Approval of ZYNRELEF™ (HTX-011) for the Management of Postoperative Pain for up...

SAN DIEGO, May 13, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatment...

4 months ago - PRNewsWire

Why Heron Therapeutics Stock Jumped Today

Investors liked the company's Q1 update.

4 months ago - The Motley Fool

Heron Stock Trading Higher After Q1 Earnings, Ahead Of HTX-011 Decision Scheduled This Week

Heron Therapeutics Inc (NASDAQ: HRTX) posted Q1 oncology care net product sales of $20 million, compared to $25.4 million a year ago, due to reduced cancer screening procedures and new patient treatment...

4 months ago - Benzinga

Heron Therapeutics (HRTX) Reports Q1 Loss, Misses Revenue Estimates

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -1.75% and -25.90%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2021 and Highlights Recent Corpor...

SAN DIEGO, May 10, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatment...

4 months ago - PRNewsWire

Want to Make Money in Biotech? Do This First

Keeping track of upcoming events is important.

Other symbols:ALKS
4 months ago - The Motley Fool

Will Heron Therapeutics (HRTX) Report Negative Q1 Earnings? What You Should Know

Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

Do Options Traders Know Something About Heron Therapeutics (HRTX) Stock We Don't?

Investors need to pay close attention to Heron Therapeutics (HRTX) stock based on the movements in the options market lately.

5 months ago - Zacks Investment Research

Heron Therapeutics (HRTX) Reports Q4 Loss, Tops Revenue Estimates

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 0.00% and 12.11%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Analysts Estimate Heron Therapeutics (HRTX) to Report a Decline in Earnings: What to Look Out for

Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises and Announces New Development Program

SAN DIEGO, Jan. 11, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatmen...

8 months ago - PRNewsWire

Heron Therapeutics (HRTX) Looks Good: Stock Adds 6.8% in Session

Heron Therapeutics (HRTX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

8 months ago - Zacks Investment Research